文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基于肺超声评估拔管失败高风险的COPD以外患者撤机:WIN IN WEAN多中心随机对照试验

Weaning of non COPD patients at high-risk of extubation failure assessed by lung ultrasound: the WIN IN WEAN multicentre randomised controlled trial.
PubMed 文献 · Crit Care · 2024-11-26
一句话结论无COPD且肺超声评分≥14的高风险患者,拔管后预防性无创通气交替经鼻高流量氧疗可减少48小时拔管后呼吸衰竭,但未降低再插管率和死亡率。

这项法国-中国多中心随机对照试验纳入无COPD、撤机自主呼吸试验期间肺超声评分(LUS)≥14的机械通气患者,干预组拔管后48小时接受预防性无创通气(NIV)交替经鼻高流量氧疗(HFNO),对照组常规氧疗。共240例随机、227例分析(干预组128例、对照组99例)。干预组48小时拔管后呼吸衰竭(PRF)发生率降低,相对风险0.52(95%CI 0.31-0.88,p=0.01),第7天获益持续,相对风险0.62(95%CI 0.44-0.96,p=0.02)。因撤机失败需重新连接机械通气未减少,其他次要结局无差异。作者认为预防性NIV交替HFNO与补救NIV治疗PRF同样有效,但更耗费资源且成本更高。

要点

  • 无COPD且自主呼吸试验期间LUS≥14的拔管高风险患者,拔管后48小时预防性NIV交替HFNO较常规氧疗降低48小时PRF:相对风险0.52(95%CI 0.31-0.88,p=0.01)。
  • 第7天PRF获益持续:相对风险0.62(95%CI 0.44-0.96,p=0.02)。
  • 预防性NIV交替HFNO未减少因撤机失败需重新连接机械通气,再插管率、28天无呼吸机天数、ICU住院时间及28天和90天死亡率均无差异。
  • 发生PRF后接受补救NIV者,对照组44%避免再插管,干预组仅12%避免再插管(p=0.008)。
  • 从资源利用角度,预防性NIV交替HFNO较常规氧疗加补救NIV更耗费资源且成本更高,以达到相同临床结局。

适用人群与场景

  • 无慢性阻塞性肺疾病(COPD)的机械通气患者,撤机自主呼吸试验期间肺超声评分(LUS)≥14定义为拔管后呼吸衰竭(PRF)高风险。
  • 法国-中国多中心随机对照试验人群,共240例随机、227例分析(干预组128例、对照组99例)。

诊断标准与关键阈值

  • 拔管后呼吸衰竭(PRF)定义:以下体征中满足2项——SpO2<90%;呼吸频率>30次/分;高碳酸血症;呼吸源性血流动力学和/或神经系统紊乱。
  • 拔管失败高风险定义:自主呼吸试验期间肺超声评分(LUS)≥14。

处置流程与药物剂量

  • 干预组:拔管后48小时给予预防性无创通气(NIV)交替经鼻高流量氧疗(HFNO)。
  • 对照组:使用常规氧疗。
  • 干预组临床医生知晓LUS结果,对照组医生保持盲态。

红旗征与不能漏的情况

  • 拔管后呼吸衰竭(PRF):SpO2<90%、呼吸频率>30次/分、高碳酸血症、呼吸源性血流动力学和/或神经系统紊乱中满足2项。

研究设计与关键结果

  • 多中心随机对照试验,240例随机、227例分析(干预组128例、对照组99例),无COPD且LUS≥14的拔管高风险患者。
  • 主要终点48小时PRF:干预组较对照组降低,相对风险0.52(95%CI 0.31-0.88,p=0.01)。
  • 第7天PRF:干预组较对照组降低,相对风险0.62(95%CI 0.44-0.96,p=0.02)。
  • 因撤机失败需重新连接机械通气未减少;其他次要结局(第7天再插管、28天无呼吸机天数、ICU住院时间、28天和90天死亡率)组间无差异。
  • 发生PRF并接受补救NIV者中,避免再插管比例对照组44% vs 干预组12%(p=0.008)。
  • 预防性NIV交替HFNO较常规氧疗加补救NIV更耗费资源且成本更高,以达到相同临床结局。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(法国-中国)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对无COPD且自主呼吸试验期间LUS≥14的拔管高风险患者,拔管后48小时预防性NIV交替HFNO可减少48小时和第7天PRF,但未降低再插管率和死亡率;作者认为该策略与补救NIV治疗PRF同样有效,但更耗费资源且成本更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Postextubation respiratory failure (PRF) frequently complicates weaning from mechanical ventilation and may increase morbidity/mortality. Noninvasive ventilation (NIV) alternating with high-flow nasal oxygen (HFNO) may prevent PRF.

METHODS: Ventilated patients without chronic obstructive pulmonary disease (COPD) and at high-risk of PRF defined as a lung ultrasound score (LUS) ≥ 14 assessed during the spontaneous breathing trial, were included in a French-Chinese randomised controlled trial. PRF was defined by 2 among the following signs: SpO2 < 90%; Respiratory rate > 30 /min; hypercapnia; haemodynamic and/or neurological disturbances of respiratory origin. In the intervention group, prophylactic NIV alternating with HFNO was administered for 48 h following extubation. In the control group, conventional oxygen was used. Clinicians were informed on the LUS in the intervention group, those in the control group remained blind. The primary outcome was the incidence of PRF 48 h after extubation. Secondary outcomes were incidence of PRF and reintubation at day 7, number of ventilator-free days at day 28, length of ICU stay and mortality at day 28 and 90.

RESULTS: Two hundred and forty patients were randomised and 227 analysed (intervention group = 128 and control group = 99). PRF at H48 was reduced in the intervention group compared to the control group: relative risk 0.52 (0.31 to 0.88), p = 0.01. The benefit persisted at day 7: relative risk 0.62 (0.44 to 0.96), p = 0.02. Weaning failure imposing reconnection to mechanical ventilation was not reduced. In patients who developed PRF and were treated by rescue NIV, reintubation was avoided in 44% of control patients and in 12% of intervention patients (p = 0.008). Other secondary outcomes were not different between groups. From a resource utilisation standpoint, prophylactic NIV alternating with HFNO was more demanding and costly than conventional oxygen with rescue NIV to achieve same clinical outcome.

CONCLUSIONS: Compared to conventional oxygenation, prophylactic NIV alternating with HFNO significantly reduced postextubation respiratory failure but failed to reduce reintubation rate and mortality in patients without COPD at high risk of extubation failure. Prophylactic NIV alternating with HFNO was as efficient as recue NIV to treat postextubation respiratory failure.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Rouby JJ, Perbet S, Quenot JP, et al. Weaning of non COPD patients at high-risk of extubation failure assessed by lung ultrasound: the WIN IN WEAN multicentre randomised controlled trial. Crit Care. 2024. PMID: 39593129. doi:10.1186/s13054-024-05166-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。